Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice. / Christiansen, Søren Hofman Oliveira; Olesen, Mikkel Vestergaard; Gøtzsche, Casper René; Woldbye, David Paul Drucker.

In: Neuropeptides, Vol. 48, No. 6, 16.09.2014, p. 335-44.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Christiansen, SHO, Olesen, MV, Gøtzsche, CR & Woldbye, DPD 2014, 'Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice', Neuropeptides, vol. 48, no. 6, pp. 335-44. https://doi.org/10.1016/j.npep.2014.09.004

APA

Christiansen, S. H. O., Olesen, M. V., Gøtzsche, C. R., & Woldbye, D. P. D. (2014). Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice. Neuropeptides, 48(6), 335-44. https://doi.org/10.1016/j.npep.2014.09.004

Vancouver

Christiansen SHO, Olesen MV, Gøtzsche CR, Woldbye DPD. Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice. Neuropeptides. 2014 Sep 16;48(6):335-44. https://doi.org/10.1016/j.npep.2014.09.004

Author

Christiansen, Søren Hofman Oliveira ; Olesen, Mikkel Vestergaard ; Gøtzsche, Casper René ; Woldbye, David Paul Drucker. / Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice. In: Neuropeptides. 2014 ; Vol. 48, No. 6. pp. 335-44.

Bibtex

@article{7b8672c81dd8425d9bb274ab2c9b0f18,
title = "Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice",
abstract = "Neuropeptide Y (NPY) causes anxiolytic- and antidepressant-like effects after central administration in rodents. These effects could theoretically be utilized in future gene therapy for anxiety and depression using viral vectors for induction of overexpression of NPY in specific brain regions. Using a recombinant adeno-associated viral (rAAV) vector, we addressed this idea by testing effects on anxiolytic- and depression-like behaviours in adult mice after overexpression of NPY transgene in the amygdala and/or hippocampus, two brain regions implicated in emotional behaviours. In the amygdala, injections of rAAV-NPY caused significant anxiolytic-like effect in the open field, elevated plus maze, and light-dark transition tests. In the hippocampus, rAAV-NPY treatment was associated with anxiolytic-like effect only in the elevated plus maze. No additive effect was observed after combined rAAV-NPY injection into both the amygdala and hippocampus where anxiolytic-like effect was found in the elevated plus maze and light-dark transition tests. Antidepressant-like effects were not detected in any of the rAAV-NPY injected groups. Immobility was even increased in the tail suspension and forced swim tests after intra-amygdaloid rAAV-NPY. Taken together, the present data show that rAAV-NPY treatment may confer non-additive anxiolytic-like effect after injection into the amygdala or hippocampus, being most pronounced in the amygdala",
author = "Christiansen, {S{\o}ren Hofman Oliveira} and Olesen, {Mikkel Vestergaard} and G{\o}tzsche, {Casper Ren{\'e}} and Woldbye, {David Paul Drucker}",
year = "2014",
month = sep,
day = "16",
doi = "10.1016/j.npep.2014.09.004",
language = "English",
volume = "48",
pages = "335--44",
journal = "Neuropeptides",
issn = "0143-4179",
publisher = "Churchill Livingstone",
number = "6",

}

RIS

TY - JOUR

T1 - Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice

AU - Christiansen, Søren Hofman Oliveira

AU - Olesen, Mikkel Vestergaard

AU - Gøtzsche, Casper René

AU - Woldbye, David Paul Drucker

PY - 2014/9/16

Y1 - 2014/9/16

N2 - Neuropeptide Y (NPY) causes anxiolytic- and antidepressant-like effects after central administration in rodents. These effects could theoretically be utilized in future gene therapy for anxiety and depression using viral vectors for induction of overexpression of NPY in specific brain regions. Using a recombinant adeno-associated viral (rAAV) vector, we addressed this idea by testing effects on anxiolytic- and depression-like behaviours in adult mice after overexpression of NPY transgene in the amygdala and/or hippocampus, two brain regions implicated in emotional behaviours. In the amygdala, injections of rAAV-NPY caused significant anxiolytic-like effect in the open field, elevated plus maze, and light-dark transition tests. In the hippocampus, rAAV-NPY treatment was associated with anxiolytic-like effect only in the elevated plus maze. No additive effect was observed after combined rAAV-NPY injection into both the amygdala and hippocampus where anxiolytic-like effect was found in the elevated plus maze and light-dark transition tests. Antidepressant-like effects were not detected in any of the rAAV-NPY injected groups. Immobility was even increased in the tail suspension and forced swim tests after intra-amygdaloid rAAV-NPY. Taken together, the present data show that rAAV-NPY treatment may confer non-additive anxiolytic-like effect after injection into the amygdala or hippocampus, being most pronounced in the amygdala

AB - Neuropeptide Y (NPY) causes anxiolytic- and antidepressant-like effects after central administration in rodents. These effects could theoretically be utilized in future gene therapy for anxiety and depression using viral vectors for induction of overexpression of NPY in specific brain regions. Using a recombinant adeno-associated viral (rAAV) vector, we addressed this idea by testing effects on anxiolytic- and depression-like behaviours in adult mice after overexpression of NPY transgene in the amygdala and/or hippocampus, two brain regions implicated in emotional behaviours. In the amygdala, injections of rAAV-NPY caused significant anxiolytic-like effect in the open field, elevated plus maze, and light-dark transition tests. In the hippocampus, rAAV-NPY treatment was associated with anxiolytic-like effect only in the elevated plus maze. No additive effect was observed after combined rAAV-NPY injection into both the amygdala and hippocampus where anxiolytic-like effect was found in the elevated plus maze and light-dark transition tests. Antidepressant-like effects were not detected in any of the rAAV-NPY injected groups. Immobility was even increased in the tail suspension and forced swim tests after intra-amygdaloid rAAV-NPY. Taken together, the present data show that rAAV-NPY treatment may confer non-additive anxiolytic-like effect after injection into the amygdala or hippocampus, being most pronounced in the amygdala

U2 - 10.1016/j.npep.2014.09.004

DO - 10.1016/j.npep.2014.09.004

M3 - Journal article

C2 - 25267070

VL - 48

SP - 335

EP - 344

JO - Neuropeptides

JF - Neuropeptides

SN - 0143-4179

IS - 6

ER -

ID: 136428125